Patents Assigned to Genentech
  • ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20140030282
    Abstract: The invention provides anti-CD79b antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: July 8, 2013
    Publication date: January 30, 2014
    Applicant: Genentech, Inc.
    Inventors: Paul Polakis, Andrew Polson, Susan Diane Spencer, Shang-Fan Yu, Bing Zheng
  • Serine/threonine kinase inhibitors
    Patent number: 8637537
    Abstract: Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: January 28, 2014
    Assignee: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, James Crawford, Wendy Lee, Simon Mathieu, Joachim Rudolph
  • Pyrazolopyrimidine JAK inhibitor compounds and methods
    Patent number: 8637526
    Abstract: The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: January 28, 2014
    Assignee: Genentech, Inc.
    Inventors: Jeffrey Blaney, Paul A. Gibbons, Emily Hanan, Joseph P. Lyssikatos, Steven R. Magnuson, Richard Pastor, Thomas E. Rawson, Aihe Zhou, Bing-Yan Zhu
  • Growth hormone variants
    Patent number: 8637646
    Abstract: The invention provides variants of human growth hormone having an amino acid substitution at amino acid residue R77, numbered from the N-terminus of 191-amino add human growth hormone as well as nucleic acid molecules encoding these variants.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: January 28, 2014
    Assignee: Genentech, Inc.
    Inventors: James A. Wells, Brian C. Cunningham
  • PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA
    Publication number: 20140024078
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Application
    Filed: July 18, 2013
    Publication date: January 23, 2014
    Applicant: GENENTECH, INC.
    Inventors: Martin Gawlitzek, Shun Luo, Christina Teresa Petraglia
  • METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY
    Publication number: 20140023639
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 23, 2014
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Herbert Andres, Sanne Lysbet De Haas, Rebecca Elliott, Johann Karl, Yu-Ju Gloria Meng, Gregory D. Plowman, Stefan Scherer, Norbert Wild
  • Apoptotic anti-IgE antibodies
    Patent number: 8632775
    Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: January 21, 2014
    Assignee: Genentech, Inc.
    Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
  • Methods of using angiopoietin-like 4 protein to stimulate proliferation of pre-adipocytes
    Patent number: 8633155
    Abstract: ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: January 21, 2014
    Assignee: Genentech, Inc.
    Inventors: Hanspeter Gerber, Stuart Bunting, Xiao Huan Liang
  • CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) BIOMARKERS
    Publication number: 20140017230
    Abstract: The present application describes chronic lymphocytic leukemia (CLL) biomarkers. In particular, the invention concerns miRNA151 3p, miRNA409 3p, PTK2, and/or PI3K as biomarkers for patient selection in CLL, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, and methods of advertising related thereto.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 16, 2014
    Applicants: HOFFMANN-LA ROCHE INC., GENENTECH, INC.
    Inventors: DAVID DORNAN, GUILLEMETTE DUCHATEAU-NGUYEN, TRI QUANG NGUYEN, GIUSEPPE PALERMO, MARTIN WEISSER, RU-FANG YEH
  • METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY
    Publication number: 20140017231
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 16, 2014
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: HOFFMANN-LA ROCHE INC., GENENTECH. INC.
  • METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY
    Publication number: 20140017232
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 16, 2014
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: HOFFMANN-LA ROCHE INC., GENENTECH. INC.
  • Antibodies binding IL-1 related polypeptides
    Patent number: 8628777
    Abstract: The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: January 14, 2014
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Guohua James Pan
  • EGFR MUTATIONS
    Publication number: 20140011821
    Abstract: The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
    Type: Application
    Filed: August 21, 2013
    Publication date: January 9, 2014
    Applicant: GENENTECH, INC.
    Inventor: Somasekar Seshagiri
  • EXPRESSION AND SECRETION SYSTEM
    Publication number: 20140011981
    Abstract: The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 9, 2014
    Applicant: GENENTECH, INC.
    Inventors: Devin Tesar, Xiaocheng Chen, Mark Dennis, Isidro Hotzel
  • Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
    Patent number: 8623889
    Abstract: The invention provides novel compounds having the general formula: wherein X1 is N or N+O?, and one of X2, X3 and X4 is N or N+—O? and the remainder of X2, X3 and X4 is C. R2, R3, R4, R5, R6. A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: January 7, 2014
    Assignee: Genentech, Inc.
    Inventors: Joseph P. Lyssikatos, Lewis J. Gazzard, Emily Hanan, Samuel Kintz, Hans Edward Purkey
  • Variant Hhip1 protein and methods and uses thereof
    Patent number: 8623997
    Abstract: The present invention is directed to derivatives of Hhip1 and methods of using the same for treatment and diagnosis of cancer in mammals.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: January 7, 2014
    Assignees: Curis, Inc., Genentech, Inc.
    Inventors: Ivan Bosanac, Sarah G. Hymowitz, Robert A. Lazarus, Henry R. Maun, Suzanna J. Scales, Xiaohui Wen
  • Zymogen activators
    Patent number: 8623821
    Abstract: Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: January 7, 2014
    Assignee: Genentech, Inc.
    Inventors: Kyle E. Landgraf, Robert A. Lazarus
  • TREATMENT OF DISORDERS WITH ALTERED VASCULAR BARRIER FUNCTION
    Publication number: 20140005113
    Abstract: The present invention provides methods of using RASIP1 agonists and antagonists to modulate vascular barrier function and regulate new vessel formation, and to treat related disorders.
    Type: Application
    Filed: September 10, 2013
    Publication date: January 2, 2014
    Applicant: Genentech, Inc.
    Inventors: Weilan Ye, Leon H. Parker, IV, Christopher W. Wilson
  • COMBINATORIAL THERAPY
    Publication number: 20140004038
    Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
    Type: Application
    Filed: December 7, 2012
    Publication date: January 2, 2014
    Applicant: Genentech, Inc.
    Inventors: Anan Chuntharapai, Gregory D. Plowman, Marc Tessier-Lavigne, Yan Wu, Weilan Ye
  • MUTANT SMOOTHENED AND METHODS OF USING THE SAME
    Publication number: 20140004535
    Abstract: The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved aspartic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 2, 2014
    Applicants: Curis, Inc., Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Gerrit J.P. Dijkgraaf